*:Co-first author; #:Co-corresponding author
1.Li S*, Lv J*, Li Z*, Zhang Q*, Lu J, Huo X, Guo M, Liu X, Li C, Wang J, Shi H, Deng L, Chen Z, Du X. Overcoming multi-drug resistance in SCLC: a synergistic approach with venetoclax and hydroxychloroquine targeting the lncRNA LYPLAL1-DT/BCL2/BECN1 pathway. Mol Cancer. 2024 Oct 31;23(1):243.
2.Li S*, Lv J*, Zhang X*, Zhang Q, Li Z, Lu J, Huo X, Guo M, Liu X, Gao R, Gong J, Li C, Li W, Zhang T, Wang J, Chen Z#, Du X#. ELAVL4 promotes the tumorigenesis of small cell lung cancer by stabilizing LncRNA LYPLAL1-DT and enhancing profilin 2 activation. FASEB J. 2023 Oct;37(10):e23170.
3.Jianyi Lv, Yihan Liu, Jia Cui, Hongjuan Fang,Ying Wu, Xiao Zhu, Meng Guo, Changlong Li, Jingtao Dou, Zhenwen Chen, Xiaoyan Du. Profile Screening of Differentially Expressed lncRNAs of Circulating Leukocytes in Type 2 Diabetes Patients and Differences From Type 1 Diabete. Front En docrinol (Lausanne), 2022, Jan 10;12:69055.
4.Shuxin Li*, Qianqian Mao*, Zixuan Zhang, Yuqi Wang, Duoxuan Chen, Zhenwen Chen#, Jianyi Lv#. Identification of a five-gene panel to assess prognosis for gastric cancer. Biomed Res Int. 2022 Feb 9; 2022:5593619.
5.Jianyi Lyu; Xiuqian Mu; Genetic control of retinal ganglion cell genesis, Cell Mol Life Sci, 2021, 78(9): 4417- 4433.
6.Kaiyan Ma, Shuxin Li, Xueyun Huo, Meng Guo, Xiaoyan Du, Chonglong Li, Xin Liu, Jianyi Lv#, Zhenwen Chen#. Exploring the mechanism of cisplatin resistance by transcriptome sequencing and re versing the chemoresistance by autophagy inhibition in small cell lung cancer, Biochem Biophys Res Commun, 2020, 533(3): 474-480.
Honors and Awards:
1.2020, First Prize in the Scientific and Technological Achievement Award, Chinese Association for Laboratory Animal Sciences (CALAS).
2.2020, First Prize in Beijing Association for Laboratory Animal Science (BAALAS).